Discovery Assay Development of Biomarkers Predictive of Preterm Birth
June 2014 – Sera Prognostics, Inc. presented the development and analytical performance of a highly multiplexed and targeted mass spectrometry-based assay for biomarker discovery and subsequent clinical diagnostic development. Using this advanced MRM method, biomarkers were identified across multiple pathways of relevance to preterm birth.